RWM
HBIO icon

Rialto Wealth Management’s Harvard Bioscience HBIO Stock Holding History

Rialto Wealth Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-108
Closed -$475 – 1738
2025
Q3 		$475 Hold
108
– – ﹤0.01% 1269
2025
Q2 		$480 Buy
+108
New +$451 ﹤0.01% 1182

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Rialto Wealth Management's HBIO Position: Q4 2025 in Review

Rialto Wealth Management sold out of Harvard Bioscience (HBIO) in Q4 2025, closing a stake of 108 shares — an estimated $475 sold.

Rialto Wealth Management first reported a position in HBIO in Q2 2025 and held it in 2 quarters. The position peaked at $480 in Q2 2025. 64 funds tracked by Wall St. Rank hold HBIO as of Q4 2025.

  • Rialto Wealth Management reported no remaining Harvard Bioscience position as of Q4 2025 after selling out during the quarter.
  • Rialto Wealth Management sold 108 Harvard Bioscience shares in Q4 2025, an estimated $475.
  • Rialto Wealth Management first reported a position in Harvard Bioscience in Q2 2025 and held it in 2 quarters.
  • Rialto Wealth Management's Harvard Bioscience position peaked at $480 in Q2 2025.
  • 64 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2025.

Based on Rialto Wealth Management's 13F filing for Q4 2025, filed 12 Jan 2026.